Clinical Trials Sponsored by Pierian Biosciences

Total 1907 results

Neurocrine Biosciences

Enrolling by invitation

Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada

Chorea, Huntington

Canada
Neurocrine Biosciences

Active, not recruiting

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia (CAHtalyst)

Congenital Adrenal Hyperplasia

United States, Spain, Belgium, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Serbia, Sweden, United Kingdom
Persephone Biosciences

Terminated

Vaccine Observation to Include All Communities for Equitable Science (VOICES)

Vaccine Adverse Reaction | Vaccine Response Impaired

United States
Pyramid Biosciences

Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Solid Tumor, Adult | Desmoplastic Small Round Cell Tumor | Brain Tumor, Primary

France, United States, Spain, Hong Kong, United Kingdom, Australia, Singapore, Germany, Korea, Republic of, Italy, Denmark
KBP Biosciences

Completed

A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects

Healthy

United States
Spruce Biosciences

Active, not recruiting

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

Congenital Adrenal Hyperplasia

United States, Australia, Brazil, Canada, Denmark, Estonia, Germany, Ireland, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, Turkey, United Kingdom
Aura Biosciences

Active, not recruiting

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Ocular Melanoma | Uveal Melanoma | Choroidal Melanoma

United States
Origin Biosciences

Completed

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Molybdenum Cofactor Deficiency, Type A

United States, Spain, Israel, Norway, Turkey, United Kingdom
Assembly Biosciences

Terminated

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

China
Neurocrine Biosciences

Completed

A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures

Focal Onset Seizure | Focal Onset Epilepsy

Spain, Belgium, Czechia, France, Italy, Australia, Hungary, United Kingdom
Aura Biosciences

Terminated

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM) (IL)

Choroidal Melanoma | Indeterminate Lesions

United States
MBX Biosciences

Completed

Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

Healthy

United States
Asana BioSciences

Completed

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Atopic Dermatitis

United States, Germany, Canada
Assembly Biosciences

Completed

A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-H3733 in Subjects With Chronic Hepatitis B Virus Infection

Chronic Hepatitis B

Singapore, Hong Kong, Bulgaria, Moldova, Republic of, New Zealand, Romania
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
Asana BioSciences

Completed

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Dermatitis, Atopic | Dermatitis, Eczematous | Dermatitis Eczema

United States, Canada
Assembly Biosciences

Terminated

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

Chronic Hepatitis B

United States, Canada, Hong Kong, New Zealand, United Kingdom
Asana BioSciences

Completed

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

Healthy Volunteers

United States
Knopp Biosciences

Completed

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma (EXHALE-1)

Asthma | Eosinophilic Asthma

United States
Codiak BioSciences

Completed

A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors

Advanced Solid Tumor

United States, United Kingdom
Pyramid Biosciences

Completed

A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers

Drug-drug Interaction

United States
Assembly Biosciences

Terminated

A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors

Chronic Hepatitis B

Hong Kong, United States, New Zealand
Codiak BioSciences

Terminated

A Phase 1/2a Study of CDK-003 in Patients With Cutaneous T-Cell Lymphoma (CTCL). (Part B)

Cutaneous T-cell Lymphoma (CTCL)

United Kingdom
Neurocrine Biosciences

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia

CAH - Congenital Adrenal Hyperplasia

United States
Flame Biosciences

Completed

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

Healthy Subjects

United States
Catalyst Biosciences

Terminated

Screening Study to Identify Patients With Complement Factor I Deficiencies

Previous Diagnosis With a Complement-mediated Disease and/or With Clinical Manifestations Reasonably Associated With Complement Factor I Deficiency

United States
Neurocrine Biosciences

Completed

Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Pyramid Biosciences

Completed

A Study to Evaluate the Skin Irritation Potential of PBI-100 Topical Cream in Healthy Participants

Healthy Volunteers

United States
Kaleido Biosciences

Completed

A Clinical Study to Assess the Effects of KB295 in Patients With Ulcerative Colitis (UC) on Gut Microbiota Structure and Function

Ulcerative Colitis

Ireland, United States
Flame Biosciences

Withdrawn

FL-101 in Surgically Resectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer
Catalyst Biosciences

Terminated

Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

Factor VII Deficiency | Hemophilia A With Inhibitor | Glanzmann Thrombasthenia

United States, India, Italy, Russian Federation, Ukraine
Catalyst Biosciences

Completed

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

Hemophilia A | Hemophilia B | Hemophilia A With Inhibitor | Hemophilia B With Inhibitor | Hemophilia A Without Inhibitor | Hemophilia B Without Inhibitor

Bulgaria, Russian Federation
Kaleido Biosciences

Completed

An Observational Clinical Study to Evaluate COVID-19 Symptoms in "Long Hauler" Patients Who Participated in K031-120 or K032-120

COVID-19

United States
Neurocrine Biosciences

Completed

Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome

Tourette Syndrome

United States, Puerto Rico
Hemera Biosciences

Withdrawn

Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

Geographic Atrophy | Dry Age-related Macular Degeneration | Gene Therapy | Intravitreal Injection
Neurocrine Biosciences

Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Tourette Syndrome

United States
Assembly Biosciences

Terminated

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic Mild

United States, Canada
Assembly Biosciences

Completed

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Chronic Hepatitis B

United States, Canada, Hong Kong, New Zealand, United Kingdom
Assembly Biosciences

Completed

A Study to Evaluate the Mass Balance Absorption and AME of VBR

Chronic Hepatitis B

United States
Kaleido Biosciences

Completed

A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects

Healthy

United States
Neurocrine Biosciences

Completed

Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome

Tourette Syndrome

United States
Assembly Biosciences

Completed

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Chronic Hepatitis B

United States
Kaleido Biosciences

Completed

Clinical Food Study to Evaluate the Effect of KB195 on Gut Nitrogen Metabolism in Patients With Urea Cycle Disorders

Urea Cycle Disorders

Switzerland
Assembly Biosciences

Completed

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Taiwan, Australia, Hong Kong, United Kingdom
Asana BioSciences

Terminated

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Prostate Neoplasms, Castration-resistant

United States
Translational Biosciences

Completed

Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Multiple Sclerosis

Panama
Neurocrine Biosciences

Completed

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Catalyst Biosciences

Completed

Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia

Hemophilia A

United States, Belgium, Hungary, Italy, New Zealand, South Africa, Turkey, United Kingdom
Neurocrine Biosciences

Withdrawn

An Exploratory Study of NBI-34060 Capsules and Next Day Functioning

Insomnia

United States
YM BioSciences

Completed

Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer

Metastatic/Recurrent Breast Cancer

Russian Federation, Georgia, Ukraine

Clinical Trials Sponsored by Pierian Biosciences

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations